IR情報

2020/11/02~2021/03/30

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2021
04/0214:00 日本新規参入インサイト・バイオサイエンシズ・ジャパン合同会社の胆道癌治療薬「ペマジール錠4.5mg」スズケングループによる一社流通受託のお知らせ
03/3015:30 「新型コロナワクチン接種前後の症状管理・共有PHRプラットフォーム」をWelbyと共同展開
03/304,5904,5904,4304,435-2.63%209,8004583億3100万+4.6%
03/294,5654,6004,5154,555+1%294,9004707億3229万+7.58%
03/2614:00 エンブレース株式会社の株式取得(子会社化)に関するお知らせ
03/264,5004,5554,4854,510+1.46%295,0004660億8181万+6.82%
03/254,4754,5004,4404,445-0.11%253,1004593億6444万+5.46%
03/244,4854,4954,4254,450-0.22%280,8004598億8116万+5.7%
03/234,4954,5354,4454,460+0.22%208,2004609億1461万+6.09%
03/224,3954,4854,3654,450+1.25%296,3004598億8116万+5.95%
03/194,3504,4054,3204,395+1.62%372,0004541億9724万+4.77%
03/184,2654,3504,2554,325+2.49%272,2004469億6315万+3.2%
03/174,2004,2354,1904,220+0.12%193,9004361億1203万+0.74%
03/164,1404,2204,1354,215+2.68%203,3004355億9530万+0.55%
03/154,1104,1404,0904,105+0.12%164,5004242億2746万-2.05%
03/1215:00 代表取締役の異動(追加選定)に関するお知らせ
03/124,1154,1204,0354,1000%408,6004237億1074万-2.22%
03/114,1154,1254,0504,100-0.61%269,1004237億1074万-2.33%
03/104,1554,1954,1004,125-1.67%296,6004262億9434万-1.74%
03/094,1254,2304,0854,195+2.57%286,6004335億2842万0%
03/084,1554,1554,0454,090-0.24%138,0004226億7729万-2.36%
03/054,0504,1054,0254,100+2.12%202,2004237億1074万-2.08%
03/044,0854,0853,9704,015-2.55%205,3004149億2649万-4.02%
03/034,1404,1404,0904,120-0.12%209,4004257億7762万-1.46%
03/0213:00 パナソニックとの協業による医薬品定温輸送ボックス「VIXELL」のレンタルサービス事業を開始
03/024,1204,1504,0854,125+0.73%306,1004262億9434万-1.2%
03/014,1004,1354,0404,095+0.86%251,6004231億9401万-1.8%
02/264,1604,1604,0604,060-2.4%292,6004195億7697万-2.59%
02/2514:00 監査等委員会設置会社への移行に関するお知らせ
02/254,1854,1854,1404,1600%101,1004299億1138万-0.17%
02/244,2704,2704,1554,160-2.46%127,2004299億1138万-0.12%
02/224,3254,3604,2604,265-0.23%122,1004407億6251万+2.45%
02/194,3004,3304,2754,275-1.27%164,6004417億9595万+2.84%
02/184,3904,4004,3154,330+0.46%185,0004474億7987万+4.29%
02/174,3804,3804,2904,310-0.12%109,5004454億1299万+4.26%
02/164,3554,3604,2954,315-0.92%84,2004459億2971万+4.81%
02/154,3704,3854,3404,355+0.58%94,2004500億6348万+6.32%
02/124,3454,3604,3054,330+1.05%180,3004474億7987万+6.28%
02/104,2454,3004,2204,285+0.47%105,0004428億2939万+5.75%
02/094,2854,2854,2254,265-0.93%124,1004407億6251万+5.86%
02/084,2054,3154,2054,305+2.5%189,5004448億9627万+7.41%
02/054,1454,2054,0804,200+1.33%270,6004340億4514万+5.4%
02/044,1554,2204,0904,145-1.78%249,1004283億6122万+4.49%
02/0315:00 特別損失の計上および業績予想の修正に関するお知らせ
02/0315:00 2021年3月期第3四半期決算短信〔日本基準〕(連結)
02/034,0754,2204,0554,220+2.93%248,1004361億1203万+6.86%
02/024,0504,1054,0254,100+1.11%215,8004237億1074万+4.33%
02/014,0904,1354,0554,055+0.12%192,3004190億6025万+3.55%
01/294,0354,0804,0304,050+0.25%189,6004185億4353万+3.74%
01/283,9404,0603,9304,040+0.87%236,2004175億1009万+3.75%
01/273,9904,0103,9404,005+1.14%171,3004138億9305万+2.98%
01/263,9854,0503,9453,960+0.13%135,6004092億4256万+1.9%
01/254,0554,0553,9403,955-1.62%111,6004087億2584万+1.83%
01/224,0104,0303,9854,020-0.12%144,7004154億4321万+3.53%
01/214,0454,0904,0054,025-0.37%137,0004159億5993万+3.74%
01/204,0754,0804,0054,040-1.58%180,2004175億1009万+4.2%
01/194,0804,1304,0604,105-0.48%166,2004242億2746万+5.96%
01/184,1154,1554,1004,125+0.49%114,5004262億9434万+6.67%
01/154,1454,1904,0854,105-0.97%218,0004242億2746万+6.32%
01/143,9054,1553,8854,145+6.69%357,3004283億6122万+7.58%
01/133,8453,9053,8353,885+0.13%246,5004014億9176万+1.07%
01/123,8203,9203,8103,880+1.97%246,7004009億7504万+0.88%
01/083,7853,8253,7103,805+0.26%264,3003932億2423万-1.09%
01/073,8453,8603,7903,795+0.4%200,4003921億9079万-1.4%
01/063,7453,7903,7053,780+1.89%159,8003906億4063万-1.87%
01/053,7453,7653,6953,710-0.8%185,1003834億654万-3.89%
01/043,7903,7953,7003,740+0.27%189,3003865億687万-3.41%
2020
12/303,7753,7753,7153,730-0.67%168,9003854億7342万-3.92%
12/293,7253,7653,7203,755+1.76%191,9003880億5703万-3.54%
12/283,7653,7703,6703,690-1.34%125,6003813億3966万-5.43%
12/253,7503,7603,7253,740-0.66%70,4003865億687万-4.37%
12/243,7803,8053,7553,765+0.4%89,0003890億9047万-3.91%
12/233,8403,8403,7403,750-1.57%146,2003875億4031万-4.31%
12/223,8703,8703,7803,810-2.43%196,3003937億4095万-2.91%
12/213,9353,9603,8703,905-0.76%122,2004035億5864万-0.53%
12/183,8503,9403,8503,935+0.9%261,4004066億5896万+0.38%
12/173,9303,9303,8753,900-0.89%161,9004030億4192万-0.38%
12/163,9353,9553,9203,935-0.13%127,3004066億5896万+0.54%
12/153,9603,9603,9253,940-0.38%156,7004071億7568万+0.72%
12/143,9304,0103,9103,955-0.38%156,3004087億2584万+1.28%
12/113,9303,9803,9103,970+1.02%188,8004102億7600万+1.82%
12/103,9603,9803,9153,930-0.76%189,6004061億4224万+0.82%
12/0911:30 再発防止に向けたコンプライアンス遵守徹底の取り組みおよび取締役および執行役員報酬の減額に関するお知らせ
12/093,9403,9653,9053,960+1.41%227,9004092億4256万+1.64%
12/083,9303,9503,9053,905-0.64%200,4004035億5864万+0.41%
12/074,0004,0203,9153,9300%179,0004061億4224万+1.21%
12/043,9253,9503,9103,930+0.26%117,3004061億4224万+1.26%
12/033,8953,9653,8953,920+1.69%192,0004051億880万+1.24%
12/023,8653,9103,8203,855+0.13%271,9003983億9143万-0.23%
12/013,9303,9753,8153,850-3.51%311,8003978億7471万-0.23%
11/303,9703,9903,8453,990-0.37%747,0004123億4289万+3.45%
11/2714:00 資本業務提携に関するお知らせ
11/274,0204,0353,9854,005+0.5%251,8004138億9305万+4.08%
11/263,9804,0053,9353,985-0.5%136,2004118億2617万+3.8%
11/254,0504,0703,9704,005+0.63%228,9004138億9305万+4.6%
11/244,0054,0453,9753,980+1.14%242,5004113億945万+4.24%
11/203,8653,9353,8453,935+1.03%198,4004066億5896万+3.36%
11/193,8103,9003,8103,895+2.64%259,2004025億2520万+2.53%
11/183,8653,8703,7553,795-1.94%312,4003921億9079万+0.03%
11/173,8703,8853,8353,870-0.13%283,8003999億4160万+1.95%
11/163,8103,9203,8053,875+3.61%304,7004004億5832万+1.95%
11/133,8403,8403,7153,740-2.22%222,4003865億687万-1.73%
11/123,8203,8703,7753,825-1.42%200,5003952億9111万+0.18%
11/113,9503,9653,8353,8800%282,3004009億7504万+1.46%
11/103,8403,8903,7853,880+2.92%272,5004009億7504万+1.28%
11/093,7903,8553,7553,770-0.4%224,8003896億719万-1.69%
11/063,6153,8203,6153,785-4.54%399,7003911億5735万-1.46%
11/0515:00 業績予想の修正に関するお知らせ
11/0515:00 2021年3月期第2四半期決算短信〔日本基準〕(連結)
11/053,8553,9803,8353,965+2.59%215,9004097億5928万+2.99%
11/043,8253,8903,7853,865+1.98%250,9003994億2488万+0.16%
11/023,7803,8353,7653,790+0.66%314,9003916億7407万-2.22%
10/2714:00 提携企業各社とのデジタル治験プラットフォームの構築に向けた取組みに関するお知らせ
10/2714:00 サスメド株式会社への追加出資に関するお知らせ